About

Copious research efforts have been undertaken in MS research in the last three decades to unravel immune mechanisms in the periphery thought to be responsible for disease onset and effector mechanisms mediating CNS damage.  However, the underlying molecular causes of MS are still not understood and prognostic estimates can hardly be given to patients in the absence of valid surrogate markers.  Traditional therapeutic disease modifying regimens aim at immunomodulation or immunosuppression and were developed in the context of autoimmune research in conjunction with other diseases such as rheumatoid arthritis, Crohn’s disease and diabetes mellitus.  However, response to anti-inflammatory therapeutic interventions differs significantly between MS and other autoimmune disorders.  Moreover, in many MS patients, response to the current interventions has only limited impact on disease progression.  Finally, novel therapies in MS aimed at reducing the CNS-directed immune responses are associated with a severe risk for opportunistic CNS infection.

There is currently an urgent need to go back to basics and apply completely novel ideas and unconventional methods as well as brand new technologies to research in this area.  Now is the time to take up the challenge and, for the first time in Germany, promote interaction between strong research groups at three different sites that all have the ideal prerequisites for illuminating and expanding highly novel and innovative perspectives in MS research.  The goal of this consortium, which consists of scientists from centers in the Rhine-Main area, Münster and Munich, is to unravel the pathology of MS and develop as well as understand novel therapeutic concepts.  The ideal prerequisites for such progress are provided by effectively linking scientists from neighboring disciplines with classical neuroimmunologists, who possess a proven track record in MS research and patient care and arise from an important and internationally visible nucleus in this field.  One key aspect here is the strong bidirectional crosstalk between pure experimental research in animal models and clinical research in human systems and patients, which allows the best transfer of basic knowledge into clinical care – and vice versa.

News

Mon, 22/01/2018
Lecture by Prof. Sarosh Irani
Munich. Prof. Sarosh Irani, Co-director of the Nuffield Department of Clinical Neurosciences at Oxford University and Head of the Oxford Autoimmune Neurology Group, will present his work on “Phenotypes and molecules in autoantibody-mediated epilepsies” at the TUM Neurology Colloquium When?: Wednesday, January 24, 6:00 pm Where?: Library, 4th floor, Neuro-Kopf-Zentrum, Klinikum rechts der Isar, Munich...more
Mon, 22/01/2018
Roland Liblau: “Immune targeting of CNS neurons”
Münster. The Department of Neurology Muenster is proud to welcome the internationally renowned MS researcher Roland Liblau, Director of the Pathophysiology Research Center at Toulouse Purpan, as a guest speaker at its weekly Neurology Seminar. Prof. Liblau will give insights into “Immune targeting of CNS neurons: from mouse models to human diseases” When?: Wednesday, January […]...more
Thu, 09/11/2017
Elisabeth Schuh received SEED funding
Munich. SFB 128 researcher Elisabeth Schuh, MD, has been honoured by a young scientist’s studentship within the KKNMS SEED program. In her project „The role of the NLRP3 inflammasome in multiple sclerosis and experimental autoimmune encephalomyelitis“, Dr. Schuh analyses the influence of the NLRP3in MS. NLRP is a cytosolic protein complex in monocytes, macrophages and […]...more